Overcoming the challenges of MIF by developing novel therapeutics targeting its disease-related isoform, oxMIF, in cancer and autoimmune disorders

We discovered the key to drugging MIF

OncoOne is dedicated to developing novel therapeutics for patients living with solid tumors and autoimmune diseases. Our founders discovered the disease-related and druggable isoform of one of the most important drivers of innate and adaptive immunity: the macrophage migration inhibitory factor (MIF). The founders identified and named this new target the oxidized macrophage migration inhibitory factor or oxMIF.

MIF, a critical yet previously elusive target
Over 3,000 peer-reviewed papers detail MIF’s importance in driving tumor progression and metastases as well as inflammation. MIF is a central mediator of both innate and adaptive immunity in cancer and immunology indications that has remained elusive to drug targeting.

oxMIF, overcoming previous limitations of targeting MIF
MIF aggregates and goes through a confirmational change to oxMIF at sites of inflammation and in malignant tissue. OncoOne’s therapies specifically target oxMIF, which is only found at the site of disease.

Our therapeutic focus
We are developing oxMIF-targeting therapies for oncology and immunology indications. OncoOne’s initial focus is on treating solid tumors while we advance our second anti-oxMIF mAb to treat patients with chronic inflammatory diseases. All indications in our focus represent significant unmet medical needs.

Science & Technology
Our Pipeline

We are actively seeking partnerships, collaborations, and Series B investors in 2022 to accelerate the progression of our oxMIF pipeline assets to the clinic

contact us

experienced

flexible

innovative

responsive

collaborative

OncoOne Newsletter

“As 2022 will be a transformative year for OncoOne, we want to provide an overview of our recent achievements and upcoming events which highlight the momentum the company is building. …”

Message from the CEO, Dr. Randolf Kerschbaumer

download newsletter Q1
download newsletter Q2
download newsletter Q3

Targeting oxMIF in Oncology and Chronic Inflammation

oxMIF in Oncology

We are developing an improved, second generation anti-oxMIF antibody, ON203 for the treatment of patients living with solid tumors. ON203 is being designed for application both as a monotherapy and in combination with standard-of-care regimens in tumor indications with high unmet medical need.

learn more

oxMIF in Chronic Inflammation

Our anti-oxMIF antibody, ON104 is being developed for the treatment of severely underserved chronic inflammatory diseases and autoimmune disorders. The synergistic mechanism of action of ON104 with glucocorticoids allows its application either as monotherapy or in combination with reduced doses of glucocorticoids.
learn more